The Impact of Radiotherapy on Oligometastatic Cancer

Summary

Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR). However, there are few studies, and there is no defined clinical standard, nor are the radiobiological mechanisms that contribute to treatment response well understood. The focus should be on generating evidence to guide the personalization of radiotherapy beyond solely technological and anatomical precision. This could be achieved by recollecting clinical and biological data from patients that undergo this treatment and analyzing them to ultimately predict, with the help of artificial intelligence, which patients will be the most beneficiary and improve their survival rate.

Conditions

• Metastasis
• Metastatic Breast Cancer
• Metastatic Prostate Cancer
• Metastatic Colorectal Cancer
• Metastatic Lung Cancer

Interventions

DIAGNOSTIC_TEST

To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR).

Analyze clinical data, medical images and molecular circulating features to propose which variables serve to select the patients that will achieve complete response after SABR.

DIAGNOSTIC_TEST

To propose a diagnostic test to determine the effectiveness of SABR.

Collect blood samples at five different time points before and after treatment and analyze circulating tumoral DNA, medical images, and metabolites to monitor the effect of SABR and its effectiveness.

DIAGNOSTIC_TEST

To propose a diagnostic test for Oligometastatic Cancer (OC).

Analyze circulating tumoral DNA and metabolites from blood samples in search of the profile of OC.

Sponsors & Collaborators

• Hospital Ruber Internacional

  collaborator OTHER

• Hospital Universitario Rey Juan Carlos

  collaborator OTHER

• Quirón Madrid University Hospital

  collaborator OTHER

• Hospital de La Luz

  collaborator OTHER

• Institut Català d'Oncologia

  collaborator OTHER

• Hospital Arnau de Vilanova

  collaborator OTHER

• Hospital Universitari Sant Joan de Reus

  collaborator OTHER

• Hospital Universitario Virgen Macarena

  collaborator OTHER

• Hospital Universitario Reina Sofia de Cordoba

  collaborator OTHER_GOV

• Hospital General Universitario de Valencia

  collaborator OTHER

• Hospital Clínico Universitario de Valencia

  collaborator OTHER

• Complejo Hospitalario Universitario de Albacete

  collaborator OTHER

• Hospital de Terrassa

  collaborator OTHER

• Hospital Universitario Ramon y Cajal

  collaborator OTHER

• Hospital del Mar

  collaborator OTHER

• Hospital Provincial de Castellon

  collaborator OTHER

• Hospital de la Santa creu i Sant Pau - Barcelona

  collaborator OTHER

• HM Sanchinarro University Hospital

  collaborator OTHER

• Hospital Miguel Servet

  collaborator OTHER

• University Hospital Virgen de las Nieves

  collaborator OTHER

• Hospital Vall d'Hebron

  collaborator OTHER

• Institut Investigacio Sanitaria Pere Virgili

  lead OTHER

Principal Investigators

• Meritxell Arenas, PhD. · Universitat Rovira i Virgili, Hospital Universitari Sant Joan de Reus

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-12-01

Primary Completion

2037-12-31

Completion

2037-12-31

Countries

• Spain

Study Locations